Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells

Model T muscle CARs can treat brain tumors

Despite standard treatment with resection, radiation, and chemotherapy, glioblastoma remains a deadly disease with a dismal prognosis. Redirecting patient T cells to target the glioblastoma-associated antigen, IL13Rα2, offers a promising translational immunotherapy with the potential to make a meaningful impact for patients with this disease.